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Camouflaging State Biosimilar Laws as Pro-Patient
Legislation
Katherine Macfarlane,2
I. INTRODUCTION
In the late 1990s, a new class of medication became available to patients
suffering from chronic, debilitating autoimmune diseases such as rheumatoid
1. Associate Professor of Law, University of Idaho College of Law, B.A., Northwestern
University, J.D., Loyola Law School, Los Angeles. This essay benefited immensely from the
comments received at the 2016 Nova Law Review Symposium and the 2016 Loyola
University Chicago Beazley Institute for Health Law Symposium, where I exchanged ideas
with scholars, providers, pharmacists and patients. I was diagnosed with rheumatoid arthritis
("RA") at 13 months, and have taken many of the biologics at issue in this essay. I did not
speak openly about my struggles with RA or the medications used to treat it until recently, and
am grateful to Lene Andersen, Abby Sher, Laura Grey, Carey Tolleson and my workshop
classmates for encouraging me to do so. This essay is dedicated to the army of RA warriors
fighting for better treatment, affordable medication, and the freedom to lead the life we choose.
You can learn more about chronic illness activism via the hashtag #chroniclife.
2. From 2013 to 2015, I volunteered as a patient blogger for the website Creaky Joints,
which is affiliated with the non-profit Global Healthy Living Foundation ("GHLF"). In May
2015, I testified as a GHLF patient advocate at the Louisiana Capitol regarding a pending
biosimilar bill. In connection with my testimony, I participated in conference calls, conducted
legal research regarding the pending bill, drafted my testimony, and gave media and television
interviews. I was not compensated or reimbursed for my blogging or my Louisiana testimony
and Louisiana media efforts. In July 2015, I was a member of a panel organized by the
Congressional Arthritis Caucus, and again represented GHLF as a patient advocate. In
preparation for the Caucus, I participated in conference calls, conducted legal research, spent
approximately 5 hours preparing my remarks, and gave a press interview. GHLF reimbursed
my out-of-pocket expenses, including hotel and air travel, associated with my trip from Los
Angeles, CA to Washington, D.C., but I was not compensated for any of my additional work.
Sometime in the fall of 2015, I participated in a call with fellow GHLF patient advocates, and
described my experience testifying in Louisiana. I was not paid for that call. I also provided
recommendations to Dr. Ben Nowell, GHLF's Director of Patient-Centered research regarding
the Creaky Joints data collection project known as Arthritis Power. I was not compensated for
consulting with Dr. Nowell. Sometime in fall 2015, I was contacted by the organizers of the
February 2016 Biosimilars Market Access Summit. I was asked to participate as a presenter,
and I suggested that GHLF's legislative specialist, Steve Marmaras, also be invited to speak.
Steve signed on, and GHLF agreed to reimburse me for travel expenses connected with the
summit. Thereafter, I ceased advocacy and blogging for GHLF. In December 2015, I learned
that Steve Marmaras had withdrawn from the Biosimilars Market Access Summit. GHLF
reimbursed me for the travel expenses I incurred in connection with my trip from Idaho to
Virginia for the summit.
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arthritis (RA).3 These wonder drugs, known as biologics, gave patients who
failed conventional RA treatments' the ability to function in ways never
before imagined. For RA patients, "the availability of new biologic
treatments . . . transformed management of [their] disease . . . ."6 Biologics,
the most effective RA medication for purposes of reducing joint damage,
even help patients increase their workforce presence by reducing the number
of days they must miss from work due to their disease.
Biologics are made "by extracting cellular proteins from animals."' They
are "complex, protein-based drugs," that include medications such as insulin,
Enbrel, and other "monoclonal antibodies," which treat RA and similar
autoimmune diseases, as well as drugs that treat cancer and multiple
sclerosis. 9 The biologics used to treat RA "work by blocking the activity of a
key chemical or cell involved in inflammation that gives rise to joint swelling
3. Carol M. Ostrom, What's Behind the Whopping Price Tags on the Newest Generation
of Drugs, SEATTLE TIMES (Aug. 17, 2008, 11:36 PM), http://www.seattletimes.com/seattle-
news/health/whats-behind-the-whopping-price-tags-on-the-newest-generation-of-drugs/
("Rheumatoid arthritis is a nasty disease. Unchecked, the inflammation, destructive changes 1
to joints and dissolution of bone it causes - along with the pain - can lead to disability, lost
work time and the need for orthopedic interventions.").
4. Jeffrey R. Curtis & Jasvinder A. Singh, The Use ofBiologics in RheumatoidArthritis:
Current and Emerging Paradigms of Care, 33 CLINICAL THERAPEUTICS 679, 680-81 (2011)
(explaining that before the advent of biologics, conventional RA treatments included
combinations of non-steroidal anti-inflammatory drugs (e.g., aspirin, ibuprofen), analgesics,
glucocorticoids (e.g., prednisone, methylprednisolone), and disease-modifying anti-rheumatic
drugs.); Using Biologic Drugs to Treat Rheumatoid Arthritis, CONSUMER REP. (Mar. 2013),
http://www.consumerreports.org/cro/2013/03/using-biologic-drugs-to-treat-rheumatoid-
arthritis/index.htm# [hereinafter CONSUMER REPORTS] ("Between 30 to 70 percent of people
who have not benefitted from other rheumatoid arthritis medications experience some measure
of relief from biologics.").
5. Curtis & Singh, supra note 4, at 679, 682, 684 (explaining that in contrast to prior
methods of treatment, "biologics are highly effective in reducing RA symptoms, slowing
disease progression, and improving indices of physical function and quality of life. Clinical
responses are often rapid [as] most patients experience improvements within a few weeks of
starting treatment" or even "a few days after the first dose."); Lene Andersen, A Beginner's
Guide to RA: Biologics, HEALTHCENTRAL (Dec. 3, 2014),
http://www.healthcentral.com/rheumatoid-arthritis/c/80 106/173224/guide-biologics/
("Biologics were a revolution in RA treatment ... [causing] a seachange, not only in the rates
of control of RA, but also in how it is treated. Biologic medications are very effective in
treating RA, leading to a significant amount of people with RA achieving remission or low
disease activity.").
6. Curtis & Singh, supra note 4, at 679-80.
7. Paresh Chaudhari, The Impact of Rheumatoid Arthritis and Biologics on Employers
and Payers, 5 BIOTECHNOLOGY HEALTHCARE 37, 40 (2008).
8. Brian R. Bouggy, Follow-On Biologics Legislation: Striking a Balance Between
Innovation and Affordability, 7 IND. HEALTHL. REV. 367, 368 (2010).
9. ANDREW W. MULCAHY ET AL., THE COST SAVINGS POTENTIAL OF BIOSIMILAR DRUGS
IN THE UNITED STATES 1 (2014), https://www.rand.org/content/dam/rand/pubs/
perspectives/PE100/PE127/RANDPE127.pdf.
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and other symptoms."o
Biologics have molecular structures "usually 100 to 1,000 times" larger
than drugs like aspirin, known as "small molecule drugs."" Small molecule
drugs are made up of "relatively simple chemical compounds" that can be
easily replicated.1 2 Because biologics are structurally complex, "it is more
difficult to determine whether one biological drug is actually identical to
another." 3 Thus, there is no such thing as a "generic" biologic.' 4 Rather,
biologic copies are known as biosimilars" and replicate biologics with
"highly similar, but slightly variant, living organisms or processes .... 6
Biologics are not only the most effective kind of medication for certain
autoimmune diseases, but also the most expensive" and financially
burdensome, even for the privately insured.'" A small molecule drug costs
approximately $2 a day, whereas "[i]n 2013, the average daily cost in the
United States of a biologic drug was $45 . .. ."'9 If the Affordable Care Act's
pre-existing condition protection is eventually repealed, many patients
treated with biologics may lose their health insurance and be forced to
purchase biologics out-of-pocket (or not at all).20
10. Peter C. Taylor, Biologic Therapies for RA, in BIOLOGICS ... THE STORY So FAR: A
PATIENT GUIDE TO BIOLOGIC THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS 8
(2013), http://www.nras.org.uk/data/files/Publications/Biologics.pdf.
11. Stacey L. Worthy & John F. Kozak, Follow-On Biologics: Protecting Consumers
Through State Pharmacy Law in Light ofFDA Actions, 17 QUINNIPIAC HEALTH L.J. 207, 220
(2014).
12. Id. at 217.
13. Jason Kanter & Robin Feldman, Understanding and Incentivizing Biosimilars, 64
Hastings L.J. 57, 59 (2012) (explaining that biologics' complexity increases their cost); What
Are "Biologics" Questions and Answers, U.S. Food & Drug Admin.,
https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicaProductsandTobacco/CBE
R/ucml33077.htm (last updated Aug. 5, 2015) (stating that "most biologics are complex
mixtures that are not easily identified or characterized").
14. Kanter & Feldman, supra note 13, at 59.
15. Id.
16. Joanna M. Shepherd, Biologic Drugs, Biosimilars, and Barriers to Entry, 25 HEALTH
MATRIX 139, 143 (2015).
17. Rheumatoid Arthritis Treatment Costs, Rheumatoid Arthritis,
https://www.rheumatoidarthritis.org/treatment/costs/ (last updated Aug. 3, 2016) (describing
biologics as "the most expensive forms of medications available to patients" being treated for
RA and "[a]dding to the expense is the fact that biologics are usually administered by a
healthcare professional through an IV or by injection" which "alone creates additional health
care costs."); see also Curtis & Singh, supra note 4, at 697 ("The treatment of RA places a
substantial financial burden on healthcare systems and individual patients. Indeed, a major
problem associated with the use of biologics is cost .... Estimates show that the introduction
of biologics has increased, 3-fold, the total annual direct cost of treating RA patients.").
18. Curtis & Singh, supra note 4, at 697.
19. Jon Tanaka, "Shall" We Dance? Interpreting the BPCIA's Patent Provisions, 31
BERKELEY TECH. L.J. 659, 661 (2016).
20. Emily C. Wilson, Stop Re-Victimizing the Victims: A Call for Stronger State Laws
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Enbrel, a biologic marketed by Amgen, is the most prescribed medication
for RA.2 In 2014 alone, Amgen's Enbrel sales totaled $4.4 billion.22 Patients
who take Enbrel will not be surprised by the large sums the drug brings in for
its manufacturer; after all, an Enbrel prescription could "cost over $1,000
under a high-deductible plan."23 Moreover, Enbrel's discount card is not
available for anyone on Medicare or Medicaid. 2 4 This is particularly difficult
for RA patients, as "[a] substantial number of rheumatoid arthritis patients
are Medicare enrollees, and many struggle to afford any type of self-
injectable biologic because of the significant copays ... "25
Biosimilars are poised to shake up the American pharmaceutical market:
they are generally cheaper than biologics and are anticipated to lower costs,
Prohibiting Insurance Discrimination Against Victims of Domestic Violence, 23 AM. U. J.
GENDER, Soc. POL'Y & L. 413, 423 (2015) (commenting that the Affordable Care Act
("ACA") requires that insurance companies cover patients who have preexisting conditions;
before the ACA, a preexisting conditions could preclude someone from insurance coverage);
Nadja Popovich et al., Here's How 'Obamacare' Covered Americans with Pre-Existing
Conditions. What Happens Next?, GUARDIAN (Jan. 26, 2017),
https://www.theguardian.com/us-news/ng-interactive/2017/jan/26/obamacare-what-next-
healthcare-preexisting-conditions (listing RA and Lupus as preexisting conditions likely to
result in coverage denial before the ACA).
21. What Results Could I Expect with ENBREL?, AMGEN,
https://www.enbrel.com/rheumatoid-arthritis/ra-enbrel-treatment-results/ (last visited Apr. 9,
2017).
22. Carly Helfand, Big Question for Pfizer: Will Enbrel's EUBiosim Bring on the Pain?,
FIERCEPHARMA (Jan. 19, 2016, 11:34 AM), http://www.fiercepharma.com/sales-and-
marketing/big-question-for-pfizer-will-enbrel-s-eu-biosim-bring-on-pain.
23. CONSUMER REPORTS, supra note 4 (noting that some biologics cost more than $5,000
per week); Jack Hoadley et al., It Pays to Shop: Variation in Out-of-Pocket Costs for Medicare
PartD Enrollees in 2016, HENRY J. KAISERFAM. FOUND. (Dec. 2, 2015), http://kff.org/report-
section/it-pays-to-shop-variation-in-out-of-pocket-costs-for-medicare-part-d-enrollees-in-
2016-findings/ (noting that Medicare Part D enrollees pay approximately $4,872 per year out
of pocket for Enbrel); Alison Kodjak, Specialty Drugs Can Prove Expensive Even with
Medicare Coverage, NAT'L PUB. RADIO (Dec. 3, 2015, 10:20 AM),
http://www.npr.org/sections/health-shots/2015/12/03/458216778/specialty-drugs-can-prove-
expensive-even-with-medicare-coverage ("The out-of-pocket cost for Enbrel, a rheumatoid
arthritis medicine, for example, could reach almost $50,000 a year, if it's not covered."); Adam
Rubenfire, Rheumatoid Arthritis Drug Prices on the Rise, MODERN HEALTHCARE (Apr. 1,
2016), http://www.modernhealthcare.com/article/20160401/NEWS/160409993 (explaining
that RA drugs are often placed on a specialty tier, "which increases the patient's cost-sharing
responsibilities." "The wholesale cost of Enbrel . . . has increased 80.3% since 2013, and now
exceeds $4,000 for a 30-day supply .... ); PEW CHARITABLE TRUSTS, SPECIALTY DRUGS AND
HEALTH CARE COSTS (2015), http://www.pewtrusts.org/~/media/assets/2015/1 1/specialty-
drugs-and-health-care-costs artfinal.pdf ("[Platients who need specialty drugs face higher
out-of-pocket (OOP) costs, because health plans often require a co-insurance payment, which
is a set percentage of a drug's price. Some plans charge a co-insurance as high as 33 percent.").
24. Co-Pay, Cost, and Coverage: See How We Can Help, AMGEN,
https://www.enbrel.com/support/financial-assistance/ (last visited Apr. 9, 2017) (indicating
people with commercial or private insurance may be eligible for the ENBREL Support Co-
Pay Card; people with Medicare or Medicaid may qualify for a low-income subsidy).
25. Rubenfire, supra note 23.
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but to what extent remains to be seen.26 As a result, biosimilars make biologic
manufacturers nervous about the effect biosimilars may have on their market
share. 27 After Pfizer announced that it would begin to offer a Remicade 28
biosimilar "at a 15 percent discount to [Johnson & Johnson's] current
wholesale prices," Johnson & Johnson, which manufacturers Remicade, saw
its "shares [fall] more than 2 percent. "29
I am also nervous about the effect biosimilars will have, but what I feel is
nervous excitement. I was diagnosed with RA in 1981 at 13 months old.
Although there are more treatments available for RA patients now than there
were in 198 1,30 my disease's progression has outpaced scientific innovation.
In 2002, I began taking Remicade after less potent RA drugs, including
Celebrex and Methotrexate, failed to control my intense flares. I struggled to
walk and stand, and I was only 22 years old. I took Remicade for about six
26. Lindsay Kelly, Biologics in the Practice ofLaw, 39 HARv. J.L. & PUB. POL'Y 21, 31
(2016) (explaining that although prices are unlikely to fall "steeply," a biosimilar launched in
September 2015 was offered at a fifteen percent discount from the biologic price; the RAND
corporation also projects a thirty-five percent price decrease between 2014 and 2024 as
biosimilars are introduced); Guidance for Industry on Biosimilars: Q & As Regarding the
Implementation of the BPCI Act of 2009: Background, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/Drugs/GuidanceComplianceRegulatorylnfornation/Guidances/ucm259
806.htm (last updated Feb. 19, 2016) (describing the requirements for a biosimilar application
which needs "information demonstrating that the biological product is biosimilar to a reference
product" through various studies and that biologics have exclusivity over biosimilars for 12
years).
27. See, e.g., Tracy Staton, Aiming to Shield $14B in Sales, Abb Vie Smacks Amgen with
a Patent Suit over Humira Biosim, FIERCEPHARMA (Aug. 8, 2016, 9:58 AM),
http://www.fiercepharma.com/pharma/aiming-to-shield-14b-sales-abbvie-smacks-amgen-a-
patent-suit-over-humira-biosim (describing the patent infringement dispute between AbbVie
and Amgen regarding Amgen's new Humira biosimilar, and that some companies, like
Amgen, market and profit from both biologics and biosimilars).
28. Christian Nordqvist, Remicade (Infliximab): Uses and Cautions, MED. NEWS TODAY,
http://www.medicalnewstoday.conarticles/248273.php (last updated Mar. 7, 2017)
(explaining that Remicade is a biologic that "reduces inflammation and pain for patients with
autoimmune diseases." It works by suppressing patients' immune systems, which can make
patients who take it more susceptible to infection. Also, it must be administered intravenously,
in either a clinic or hospital). Based on my personal experience with Remicade, "infusions,"
the shorthand phrase for each Remicade treatment, take approximately three hours to
complete. Understaffed infusion centers or delays in retrieving the medication from storage
facilities can add up to two hours to the treatment time.
29. Ransdell Pierson, J&J Shares Lose Ground on Fears ofPfizer'sAnswer to Remicade,
REUTERS (Oct. 18, 2016, 1:36 PM), http://www.reuters.conarticle/us-johnson-johnson-
results-idUSKCN1215K; see Zachary Brennan, Genentech Files Complaint over Amgen 's
Development of Avastin Biosimilar, REG. AFF. PROFS. Soc'Y (Feb. 20, 2017),
http://www.raps.org/Regulatory-Focus/News/2017/02/20/26890/Genentech-Files-11
(describing a
biosimilar dispute with Avastin).
30. Katherine S. Upchurch & Jonathan Kay, Evolution of Treatment for Rheumatoid
Arthritis, 51 RHEUMATOLOGY vi28, vi28-vi30 (2012) (describing the history of RA treatments,
current treatments of RA, and future therapies for RA).
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months, but found it difficult to manage its immunosuppressant side effects
I had a constant cold. When I asked my physician how to avoid getting
sick, he recommended that I avoid crowds. This was not an option, and I
searched for a new form of treatment.
Since 2002, I have tried and failed the biologics Xeljanz, Humira, Kineret,
and Enbrel. My insurance refused to cover a prescription for the biologic
Cimzia. In July 2016, I restarted Humira, a medication I first took in 2006. I
hoped that it would work more effectively on my thirty-six-year-old body
than it did for me at twenty-six. Right away, I knew that Humira was not
working. However, my physician insisted on keeping me on Humira for six
months to see if it might eventually work. During those six months, my knees
were permanently swollen, and I used a cane to help with even the shortest
walks. My left elbow was swollen and limited in its range of motion, affecting
my ability to shower and get dressed. To combat the pain and swelling, I was
placed on twenty milligrams of prednisone, which caused insomnia and
weight gain. In December 2015, my physician finally concluded that Humira
was not working and agreed to let me try Remicade again. The doctor's nurse
stated that unless I qualified for a prescription assistance plan, I would be
responsible for twenty percent of Remicade's $8,700 per infusion cost.3 My
first two infusions would be scheduled two weeks apart, and then I would
receive the medication monthly. As a result, I faced approximately $23,000
in unexpected yearly out-of-pocket medical costs. However, with access to a
Remicade biosimilar, I can benefit from Remicade, yet pay a fraction of the
biologic's current cost. Biosimilars often sound like the financial miracle I
have been waiting for.
In 2013, I began to chronicle my experiences as an RA patient in a blog I
wrote for the online patient community Creaky Joints, a website managed by
the Global Healthy Living Foundation (GHLF).32 Through GHLF, I became
involved in lobbying efforts surrounding biosimilar legislation. In 2015, I
testified in support of legislation ultimately passed in Louisiana, which
31. Jeffrey R. Curtis et al., Cost and Effectiveness of Biologics for Rheumatoid Arthritis
in a Commercially Insured Population, 21 J. MANAGED CARE & SPECIALTY PHARMACY 318,
326 (2015) (noting the average administration cost of Remicade (Infliximab) was $1,888 for
commercially insured individual). In the author's experience, a Remicade infusion involves
the following costs: price of the biologic itself; pre-infusion steroid and pain relief medication;
and costs associated with an out-patient surgical procedure, including IV insertion and
monitoring of patient vitals. I have been informed by the hospital that administers my
Remicade that the cost of the medication is around $8,700, exclusive of the additional costs
related to infusing the drug. There are, of course, other costs-the lost wages caused by a
three-hour infusion and its side effects, as well as the physical pain caused by insertion of a
large needle that remains in a patient's vein for around three hours.
32. Kat Macfarlane: Articles, GLOBAL HEALTHY LIVING FOUND.: CREAKY JOINTS,
https://creakyjoints.org/author/katmacfarlane/ (last visited Apr. 9, 2017) (collection of
eighteen essays written for CREAKY JOINTS).
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required physician notification within five days after a biosimilar was
exchanged for a biologic.33 Since then, my perspective on laws like the one
passed in Louisiana changed. I no longer think that notification is necessary.
In fact, I am concerned that notification provisions only impede patients'
access to biosimilars. Biologics are often shipped to patients by specialty
pharmacies. There is some delay between the time a medication is prescribed
and when it is received-shipping from a special pharmacy requires the
pharmacy to verify when the patient can receive the medication, as it often
needs to be refrigerated upon arrival. Until that information is received, the
medication will not ship. Once it ships, unless a patient pays for express
delivery, the medication arrives within several days of mailing. A patient
may receive notification of an exchange before she receives the medication
itself. This abnormal procedure may discourage the patient from taking a
required dose on time, and may delay or halt future use of the biosimilar. The
notification provision communicates to the patient that something is amiss,
and may dissuade the patient from accessing an equally effective and
potentially cheaper form of treatment.
This article is inspired by my experience as a patient and advocate. It
identifies the stakeholders who have shaped state biosimilar legislation and
argues that not all stakeholders are represented.
Following this introduction, Part II compares federal biosimilar regulation
with state biosimilar regulation. Part III describes the flaws of state biosimilar
regulation. The essay concludes with a recommendation that state legislative
hearings and access to state legislators considering sponsorship of biosimilar
legislation be driven by patient voices and patient demands.
II. BIOSIMILAR REGULATION
Biosimilars are regulated through both federal and state legislation.34
Federal legislation established an abbreviated market license pathway for
biosimilars and set guidelines for the circumstances in which a pharmacist
may exchange a biologic for a biosimilar.35 At the state level, legislation
33. LA. STAT. ANN. § 37:1164(16), (58); 1226.1 (2015); Katherine Macfarlane, Patient
Advocate, Glob. Health Living Found., Testimony at House of Representatives Health and
Welfare Committee Consideration of HB 319 (May. 6, 2015),
https://www.50statenetwork.org/wp-content/uploads/2015/05/GHLF-LA-Kat-HB-319-
Testimony-5-6-15-FINAL8.pdf.
34. Jesse C. Vivian, Legal Aspects ofBiosimilars, 41 U.S. PHARMACIST 16, 17 (2016).
35. Information on Biosimilars, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAppr
oved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ (last updated May
10, 2016) (noting the Public Health Service Act was amended "to create an abbreviated
licensure pathway for biological products" that are biosimilar or interchangeable "with an
FDA-licensed biological product").
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targets the kind of notice that must be provided to doctors and/or patients
when substitution occurs, adding an additional step to the relatively
straightforward substitution procedure envisioned at the federal level.36 Both
federal and state biosimilar regulations have been the subject of intense
debate. Generally, biologic manufacturers prefer regulation that
differentiates their products from biosimilars.37 They argue that safety
requires specific naming, labeling, and notification rules.38 Luckily, the FDA
issued draft guidance regarding naming and labeling conventions.39
Nevertheless, biosimilar manufacturers, by contrast, prefer laws that do not
hinder their products' market access, either through cumbersome naming and
labeling requirements or by way of notification provisions that may raise red
flags with patients and providers about their products' safety."o A description
of these debates and the difference between federal and state legislation
follows.
A. Federal Regulation
With the Biologics Price Competition and Innovation Act of 2009
(BPCIA)," Congress created an abbreviated pathway for biosimilar
manufacturers to obtain a license to commercially market biosimilars.42
Whereas a biologic license application requires clinical data demonstrating
that the biologic is efficacious and safe, a biosimilar license application need
only show that its product is biosimilar to or interchangeable with a biologic
that has already received a license.43 A biosimilar applicant may rely on
36. Information on Biosimilars, supra note 35; Jordan Paradise, The Legal and
Regulatory Status of Biosimilars: How Product Naming and State Substitution Laws May
Impact the United States Healthcare System, 41 AM. J.L. & MED. 49, 69, 75 (2015) ("Many
laws also require patient notification or consent to the substitution . . . .").
37. Paradise, supra note 36, at 72 (stating that large biotech and pharmaceutical
companies support "unique names for biosimilars," indicating a preference for differentiation
between biologics and biosimilars).
38. Id.
39. U.S. FOOD & DRUG ADMIN., LABELING FOR BIOSIILAR PRODUCTS: GUIDANCE FOR
INDUSTRY (2016) [hereinafter LABELING FOR BIOSIMILARS].
40. Id. at 72-73.
41. 42 U.S.C.A. § 262 (West 2015); Jenny M. Alsup, You Can Dance if You Want To?
Initial Interpretations ofthe BPCIA's Patent Dance with Sandoz and Amgen, 8 HASTINGS SCI.
& TECH. L.J. 137, 140 (2016) (explaining that the BCPIA, in addition to creating a biosimilar
"statutory pathway," also "lays out a scheme for litigation of related patent issues").
42. Amgen, 794 F.3d at 1351. Sandoz filed a petition for a writ of certiorari, and Amgen
cross-petitioned. Certiorari was granted on January 13, 2017. The Supreme Court will be
tasked with resolving issues regarding when biosimilar manufacturers must give biologic
manufacturers notice of their intent to market a biosimilar under the BPCIA. See Sandoz Inc.
v. Amgen Inc., SCOTUSBLOG, http://www.scotusblog.com/case-files/cases/sandoz-inc-v-
amgen-inc/ (last visited Apr. 9, 2017) (listing the issues, proceedings, and orders of the case).
43. Amgen, 794 F.3d at 1351.
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"publicly-available information regarding the [FDA]'s previous
determination that the reference product is safe, pure, and potent.""4 Despite
the abbreviated biosimilar license pathway, biologic manufacturers still
receive "twelve years of regulatory exclusivity," a time in which a product
that is biosimilar to the biologic cannot enter the market." A biosimilar
cannot even submit a license for four years after a biologic's license is
approved. 6
Through the BPCIA's pathway, an approved biosimilar license applicant's
drug may be found to be either biosimilar or interchangeable. If biosimilar,
the drug "is highly similar, but not identical to, the innovator drug"; if
interchangeable, "the drug is therapeutically interchangeable with the
innovator and does not adversely affect safety or efficacy."4  When a
healthcare provider prescribes a biologic, a pharmacist cannot substitute it
for a drug that is only biosimilar to the biologic. 49 A pharmacist may
exchange a biologic for a biosimilar if the biosimilar is interchangeable."o
The FDA issued draft guidance regarding biosimilar products' naming and
labeling" and will finalize this guidance by May 31, 2019.52 In August 2015,
the FDA proposed that biosimilars and biologics "have non-proprietary
names", "a 4-letter suffix . .. composed of four lowercase letters, and not
carry any meaning." 53 On June 1, 2016, the FDA published additional naming
guidance that asked biosimilar license applicants to submit up to 10 potential
44. Id. (quoting 42 U.S.C. § 262(k)(2)-(5)).
45. Kelly, supra note 26, at 24; See 42 U.S.C. § 262(k)(7)(A). Exclusivity provisions are
intended to shield "pioneering manufacturers" from competition from competitors who rely
on their research and data but do not share in the original manufacturers' costs. Gregory Dolin,
Exclusivity Without Patents: The New Frontier of FDA Regulation for Genetic Materials, 98
IOWAL. REV. 1399, 1450 (2013).
46. Kelly, supra note 26, at 25; 42 U.S.C. § 262(k)(7)(B).
47. Daniel Kadin, Taking Biosimilars to the Next Level: Why Federalizing the
Substitution of Biosimilars Promotes Innovation, Competition, and Patient Safety, 45 Sw. L.
REV. 405, 408 (2015).
48. Id.
49. Purple Book: Lists of Licensed Biological Products with Reference Product
Exclusivity and Biosimilarity or Interchangeability Evaluations, U.S. Food & Drug Admin.,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAppro
ved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm411418.htm
(last visited Apr. 9, 2017).
50. Kadin, supra note 47, at 419.
51. US FDA Proposals for Naming of Biologicals and Labelling of Biosimilars, 5
GENERICS & BIOSIMILARS INITIATIVE J. 140, 140 (2016).
52. Survey: Doctors WantFDA to Reverse Course on Biosimilar Naming, INSIDE HEALTH
POL'Y (Nov. 17, 2016), https://insidehealthpolicy.com/daily-news/survey-doctors-want-fda-l
reverse-course-biosimilar-naming.
53. FDA Issues Draft Guidance on Naming Biologicals, GENERICS & BIOSIMILARS
INITIATIVE (Apr. 9, 2015), http://www.gabionline.net/Guidelines/FDA-issues-draft-guidance-
on-naming-biologicals.
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suffixes to be used in a product's nonproprietary name.14 Within weeks, the
FDA withdrew its June 1, 2016, draft guidance, explaining that its publication
was an administrative error." In January 2017, the FDA issued yet another
naming guidance, reiterating that "biological products [such as biosimilars
should] bear a nonproprietary name that includes an FDA-designated suffix"
so that "the nonproprietary name designated for each originator biological
product, related biological product, and biosimilar product will be a proper
name that is a combination of the core name and a distinguishing suffix that
is devoid of meaning and composed of four lowercase letters."
In March 2016, the FDA issued draft guidance regarding the labeling of
biosimilar products. It recommended that "applicants incorporate relevant
data and information from the reference product labeling, with appropriate
product-specific modifications."" Whether data is relevant "will depend on
whether the applicant is seeking approval for all conditions of use (e.g.,
indication(s), dosing regimen(s)) or fewer than all conditions of use of the
reference product for the biosimilar product."5 9
The response to the FDA's draft guidance has been controversial.6 o With
respect to naming, "[b]iosimilar makers have argued that distinct names will
impede the adoption of biosimilars."1 6 i Labeling practices are also hotly
contested.6 2 Despite the debates over FDA guidance, the BPCIA's purpose is
clear: it was intended to encourage scientific innovation and to give patients
access to more affordable therapies. 63
54. Zachary Brennan, FDA Calls on Companies to Select 10 Suffices for Biosimilar,
Biologic Names, REG. AFF. PROF. Soc'Y (June 1, 2016), http://www.raps.org/Regulatory-1
Focus/News/20 16/06/01/2503 8/FDA-Calls-on-Companies-to-Select- 10-Suffixes-for-
Biosimilar-Biologic-Names-by-Preference/.
55. Zachary Brennan, FDA Withdraws Document Calling on Biosimilar Developers to
Submit 10 Random Suffixes, REG. AFF. PROF. Soc'Y (June 21, 2016),
http://www.raps.org/Regulatory-Focus/News/2016/06/21/25173/FDA-Withdraws-
Document-Calling-on-Biosimilar-Developers-to-Submit-10-Random-Suffixes/.
56. U.S. FOOD & DRUG ADMIN, NONPROPRIETARY NAMING OF BIOLOGICAL PRODUCTS:
GUIDANCE FOR INDUSTRY 1 (2017),
http://www.fda.gov/downiloads/drugs/guidances/ucm459987.pdf.
57. See LABELING FOR BIOSIMILARS, supra note 39, at 1.
58. Id. at 3.
59. Id. at 5.
60. See generally Elizabeth Callahan & Irena Royzman, FDA's Proposal for Naming
Biosimilars Pleases Some, Disappoints Others, JD SUPRA (Sept. 16, 2015),
http://www.jdsupra.com/legalnews/fda-s-proposal-for-naming-biosimilars-39306/ (providing
arguments for and against the FDA's proposal for naming biosimilars).
61. Id.
62. See Vishal Gupta & Richard Praseuth, Controversy and Guidance for Biosimilar
Labeling, 35 BIOTECHNOLOGY L. REP. 137, 137 (2016) (stating that there is controversy over
labeling of biosimilars).
63. Brian F. McMahon, The Biologics Price Competition and Innovation Act of 2009:
Legislative Imprudence, Patent Devaluation, and the False Start of a Multi-Billion Dollar
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As of December 2016, four products have been granted a biosimilars
license: Amjevita, Erelzi, Zarxio, and Inflectra. 6 ' These products are
biosimilar to, respectively, Humira, Enbrel, Neupogen, and Remicade. 65 To
date, no biologics have been deemed interchangeable.
B. State Regulation
States have considered biosimilar naming and whether to impose "patient
consent, recordkeeping, and physician notification requirements." 67 State
legislation regarding biosimilars has certain common features.68 First, state
laws permitting substitution of a biosimilar require that the FDA has deemed
the biosimilar interchangeable, a step the FDA has yet to take.69 Second, state
laws often give the prescriber the ability to prevent substitution. 70 Third, state
laws generally require some form of provider notification if substitution
occurs.7 At least twelve states require patient notification.72 Fourth, state
laws mandate that pharmacists keep additional records regarding biosimilar
Industry, 100 Ky. L.J. 635, 685 (2012); JOHN GLADSTONE MILLS III ET AL., PATENT LAW
BASICS § 12:20 (Rev. ed. 2016); Brian F. King, Emerging Market for Biosimilars: State
Legislation Should Reconcile Biosimilar Substitution Laws with Existing Laws on Generic
Substitution, 18 DEPAUL J. HEALTH CARE L. 31, 36 (2016).
64. CTR. FOR DRUG EVALUATION & RES., LIST OF LICENSED BIOLOGICAL PRODUCTS WITH
(1) REFERENCE PRODUCT EXCLUSIVITY AND (2) BIOSu\4ILARITY OR INTERCHANGEABILITY
EVALUATIONS TO DATE 1-2 (2016),
http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelop
edandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM4
39049.pdf.
65. Id (showing that the proper name for the biosimilar is the same as the biologic, just
with the 4-letter suffix); Zachary Brennan, FDA Approves Third Biosimilar in US, First for
Amgen's Blockbuster Enbrel, REG. AFF. PROF. SOC'Y (Aug. 30, 2016),
http://www.raps.org/Regulatory-Focus/News/2016/08/30/25739/FDA-Approves-Third-
Biosimilar-in-US-First-for-Amgens-Blockbuster-Enbrel/ (describing approval of Erelzi and
Zarxio); FDA Approves Amjevita, a Biosimilar to Humira, U.S. FOOD & DRUG ADMIN. (Sept.
23, 2016),
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm522243.htm
(describing Amjevita approval); Sy Mukherjee, Why These Copycat Drugs Aren 't Slashing
Best-Sellers'Prices, FORTUNE (Oct. 18, 2016), http://fortune.com/2016/10/18/pfizer-johnson-
johnson-remicade-biosimilar/ (describing limited savings offered by Remicade biosimilar
Inflectra).
66. FDA Finally Addresses Interchangeable Biosimilars, LAW360 (Feb. 28, 2017),
https://www.1aw360.com/articles/89 1538/fda-finally-addresses-interchangeable-biosimilars.
67. Shepherd, supra note 16, at 152.
68. Richard Cauchi, State Laws and Legislation Related to Biologic Medications and
Substitution of Biosimilars, NAT'L CONF. OF ST. LEGISLATURES. (Nov. 15, 2016),
http://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-
medications-and-substitution-of-biosimilars.aspx.
69. Id.
70. Id.
71. Id.
72. Id.
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substitution.73 Fifth, some states provide immunity to pharmacists who
comply with state law in making a substitution. Sixth, some laws ask a
pharmacist to compare the cost or price of a biologic versus the
interchangeable biosimilar, and in five states, substitution is only permitted
if it would result in a prescription for a lower-cost medication.
Indiana's recent biosimilar legislation exemplifies typical state
legislation. 6 It allows a pharmacist to exchange a biologic for a biosimilar
only if
(1) the FDA has deemed the biosimilar to be interchangeable; (2) the
prescriber includes a 'may substitute' instruction in the prescription; (3)
the pharmacist informs the customer of the substitution; (4) the pharmacist
notifies the prescriber within five days of substitution; (5) a record is kept
of the substitution for at least five years.
State legislation creates controversy when it regulates "physician
notification, patient consent, documentation, and record retention."7 ' As of
March 2017, 27 states and Puerto Rico passed some form of biosimilar
substitution law governing how a prescription for a biologic might be
exchanged for an interchangeable biosimilar.7 9
III. SELLING LEGISLATION AS "PATIENT-FRIENDLY"
Proponents of state biosimilar legislation have justified it as protecting
"patient safety . .. the physician-patient relationship" and "transparency and
communication between patients and their treatment care teams."8o Though
proponents of state biosimilar legislation have embraced the patient-friendly
label, these proponents represent interests that are not necessarily patient-
friendly." A closer look at the entities and individuals supporting state
biosimilar legislation suggests that the laws may not always be designed with
patients in mind.82
73. Id
74. Id
75. Id
76. Kadin, supra note 47, at 420 (stating that Indiana legislation should be a model for
biosimilar legislation).
77. Id
78. King, supra note 63, at 39.
79. Cauchi, supra note 68.
80. Leigh Purvis, A Sense of DIja Vu: The Debate Surrounding State Biosimilar
Substitution Laws, INSIGHT ON THE ISSUES, Sept. 2014, at 2,
http://www.aarp.org/content/danaarp/research/public-policyinstitute/health/2014/the-
debate-surrounding-state-biosimilar-substitution-laws-AARP-ppi-health.pdf.
8 1. Id
82. Id
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Three categories of stakeholders typically support state biosimilar
legislation: biologic manufacturers, patient advocacy groups, and physicians
who treat patients with diseases that biologics treat.83 Biologic drug
companies have an interest in protecting their market share and preventing
biosimilars from competing with their own products. 4 Patient advocacy
groups that support restrictive biosimilar legislation have been criticized as
holding views "often closely aligned with those of the drug industry.""
Physicians generally support state laws on biosimilars. However well
intentioned, physicians with patients on biologics may not necessarily speak
for their patients or have interests that align with their patients' concerns.
Louisiana's biosimilar legislation" provides an illustrative example of the
way biosimilar legislation proponents may not always be patient-friendly. In
2015, Representative Scott Simon, Chairman of the Health and Welfare
Committee, introduced House Bill 319 (HB 319) during the Louisiana
legislature's regular session." The bill sought to amend certain laws "relative
to interchangeable biological products; to provide for definitions; to provide
for licensure penalties; to require certain information to be sent to a
prescriber; and to provide for related matters." 89 HB 319 was supported by
the Coalition of State Rheumatology Organizations,9 0 the Louisiana
Oncology Society,91 and GHLF, which "represents more than 80,000
chronically ill patients."92 LouisianaBio, the Louisiana chapter of the
Biotechnology Industry Organization, an international trade organization
representing biotech companies and involved in passing numerous state
biosimilar bills, wrote a letter to the editor of The Advocate, a Baton Rouge
newspaper, supporting HB 319.93 The bill's supporters echoed a consistent
83. Jeff Evans, State Laws, Regulatory Concerns Complicate Biosimilars Landscape,
RHEUMATOLOGY NEWS (Nov. 23, 2015),
http://www.mdedge.com/rheumatologynews/article/104643/rheumatoid-arthritis/state-laws-
regulatory-concerns-complicate.
84. Purvis, supra note 80, at 1-2.
85. Id.
86. Evans, supra note 83.
87. Interchangeable Biological Products Act, H.B. No. 319, 41st Reg. Sess. 391 (La.
2015).
88. Id.
89. Id.
90. Press Release, Coal. of State Rheumatology Orgs., Biosimilars Legislation Enacted
in Louisiana (July 6, 2015), http://csro.info/app/document/8431393.
91. Support Louisiana HB 319 Legislation, LA. ONCOLOGY Soc'Y,
https://www.laoncologysociety.org/support-louisiana-hb-319-legislation/ (last visited Apr. 9,
2017).
92. Letter from Seth Ginsberg, President, Glob. Health Living Found., to Louisiana
House of Representatives (May 19, 2015), https://www.50statenetwork.org/wp-1
93. Rhonda Melancon, Letter: In Support ofAlternative Drug Treatments, ADVOCATE
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theme: without the new legislation, patients' safety would be at risk.
I testified in support of HB 319 on behalf of GHLF during a Health and
Welfare Committee hearing, as did a physician. In addition to my testimony,
I gave a radio and television interview in support of the proposed bill.
As far as I am aware, only one organization opposed the Louisiana bill.
The Academy of Managed Care Pharmacy contended that it "would place
unnecessary restrictions on the substitution of biosimilars determined to be
interchangeable with reference biologic products by the [FDA]."94 For
instance, Louisiana Pharmacy Practice Act's definition of "biologic product"
references the BPCIA's definition, but makes no distinction between
biosimilar and interchangeable products, a key distinction under the
BPCIA. 95 As explained above, a pharmacist cannot substitute a biologic for
a drug that is only biosimilar to the biologic, but may exchange a biologic for
a biosimilar if the biosimilar is interchangeable.
Moreover, pursuant to the Louisiana Pharmacy Practice Act, if a
pharmacist substitutes a biosimilar deemed interchangeable by the FDA, the
pharmacist must "[n]o later than five business days following the dispensing
of a biological product ... communicate to the prescriber the specific product
provided to the patient, including the name of the product and the
manufacturer." 9 6 Ultimately, Representative Simon's bill was signed into law
on July 1, 2015.97
After my experience in Louisiana, I was tapped by GHLF to participate in
the Congressional Arthritis Caucus' July 13, 2015, Biosimilar Briefing. I was
joined by two rheumatologists, one representing the Arthritis Foundation and
the other representing the Coalition of State Rheumatology Organizations, as
well as representatives from Amgen and Sandoz. During pre-briefing
organizational calls, I gleaned that GHLF's interests aligned with those of
Amgen and the rheumatologists. I asked whether state biosimilar laws might
be preempted by federal law and was asked to refrain from raising the issue
at the Biosimilar Briefing.
At the time, Amgen and Sandoz were engaged in litigation over a Sandoz
biosimilar that would compete with an Amgen biologic. 98 During my panel
(May 7, 2015, 3:15 PM),
http://www.theadvocate.com/baton rouge/opinion/letters/article_cc6ddcbe-5180-57c8-8f31-
144b385c799d.html.
94. Letter from Edith A. Rosato, Chief Exec. Officer, Acad. of Managed Care Pharmacy,
to Governor Bobby Jindal, State of La. (June 17, 2015),
http://amcp.org/uploadedFiles/ProductionMenu/PolicyIssuesand Advocacy/Letters,_Stat
ementsandAnalysis_-_docs/2015/gov vetoreqhb319_biosimilars.pdf.
95. LA. STAT. ANN. § 37:1164(4) (2016).
96. LA. STAT. ANN. § 37:1226.1(A).
97. Press Release, Coal. of State Rheumatology Orgs., supra note 90.
98. See JohnT. Aquino, Court EndsAmgen's 'Pointless'Biosimilar SuitAgainst Sandoz,
BLOOMBERG BNA (July 26, 2016), https://www.bna.com/court-ends-amgens-n73014445282/
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presentation, I emphasized the need to inform patients and providers alike of
medication substitution even after a biosimilar is deemed interchangeable to
a biologic. 9 Amgen and the physicians echoed my concerns. Sandoz's
representative took a more skeptical approach to biosimilar restrictions.
A closer examination of the stakeholders who advocate for state biosimilar
legislation on the grounds that it is patient-friendly is needed. Invocation of
patient safety concerns may be nothing more than a rhetorically effective way
to advance laws that may not actually help or protect patients.
A. Biologic Companies
Biologic manufacturers have been vocal supporters of state biosimilar
legislation.'o Critics argue that the Biotechnology Industry Organization
(BIO) "has waged a vast campaign at the state level to impose burdensome
requirements on pharmacists seeking to substitute FDA-approved
interchangeable biosimilars for biological products."' This is true even
though there are currently no FDA-approved interchangeable biosimilars.
BIO lobbies on behalf of over 1,100 biotechnologies around the world.10 2
BIO's lobbying efforts helped pass the first state-level biosimilar legislation
in Virginia.'0 3 Pharmacists opposed the law, arguing that it created "too much
red tape for substitution, thereby threatening the impact of biosimilars within
the state."o' In California, the entities lobbying for the bill's passage
included AbbVie, Amgen, BIO, Genentech, and PhRMA. o' Relying on their
"political power and insider influence," companies like Amgen seek to
116reduce competition and protect its market share.
With respect to biosimilars, biologic manufacturers have an easily
discernible goal: stop the introduction of products that would threaten their
market share.0 7 Labeling laws that might limit patient access as "patient-
(explaining the procedural history of Amgen's litigation over Sandoz's biosimilar).
99. In 2015, I ended my relationship with GHLF. See supra note 2.
100. PUBLIC CITIZEN, COMPETITION INHIBITORS: How BIOLOGICS MAKERS ARE
LEVERAGING POLITICAL POWER TO MAINTAIN MONOPOLIES AND KEEP PRICES SKY-HIGH 24
(2014), http://www.citizen.org/documents/report-biologics-industry-leverages-political-
power-to-maintain-monopolies-and-inflate-prices.pdf.
10 1. Id.
102. Kate Traynor, Virginia Passes Nation's First Biosimilar Substitution Law, AM.
SoC'Y HEALTH SYs. PHARMACISTS (May 15, 2013),
http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?id=3892.
103. Id.
104. Virginia Bill First to Allow Biosimilar Substitution, PHARMACY TIMES (Apr. 18,
2013), http://www.pharmacytimes.com/publications/issue/2013/april2013/virginia-bill-first-
to-allow-biosimilar-substitution.
105. PUBLIC CITIZEN, supra note 100, at 26-27.
106. Id. at 27.
107. See John Alan Little, Jr., Taking from Trailblazers: Learning from Those Who Have
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friendly" obscures the laws' real purpose and may gamer patient support
under false pretenses. However, if patients need biosimilars, stakeholders
who stymie the introduction of biosimilars have interests that are not aligned
with patients' interests. As a result, when biologic manufacturers or its
lobbyists support laws regarding its market competitors, any claims that the
laws are patient-friendly should be closely scrutinized.
B. Patient Advocacy Groups
One advocacy group, GHLF, has greatly impacted state biosimilar
legislation. GHLF has lobbied in support of state biosimilar legislation in
Missouri, Oregon, Illinois, Texas, Louisiana, North Carolina, Washington,
Colorado, and Utah.' It wrote Ohio legislators to urge passage of state
biosimilar legislation with patient notification provisions.'0 9 It also wrote
similar letters to state legislators in Montana, Hawaii, Kentucky,
Connecticut, Idaho, Oregon, and Missouri.iio It opposed legislation in
Michigan that did not include notification provisions."' GHLF's President,
Seth Ginsburg, argued that an insurer should not be able to switch patients
from a biologic to a biosimilar.112
GHLF receives support for its community and advocacy efforts from
pharmaceutical companies AbbVie, AMGEN, AstraZeneca, Bristol-Myers
Squibb, Endo, Genentech, Horizon Pharma, Janssen, Lilly, Pfizer, and
Gone Before When Approving Biosimilars, 44 GA. L. REv. 1097, 1103 (2010) (At the time the
BPCIA was passed, biologic manufacturers feared that an abbreviated biosimilar pathway
would allow biosimilars to rely on biologic manufacturers' intellectual property to lower
biosimilar production costs; "the entry of biosimilars into the market might make it impossible
to recoup [biologic manufacturers'] investment in research and development."; Eric
Sagonowsky, With Billions at Stake, Will Biosims Finally Make a Mark in the U.S. in 2017?,
FIERCEPHARMA (Dec. 22, 2016, 8:05 AM), http://www.fiercepharma.com/pharma/billions-at-
stake-a-range-bio sim-battles.
108. Victories, 50-ST. NETWORK, https://www.50statenetwork.org/victories/ (last visited
Apr. 9, 2017).
109. Letter from Seth Ginsburg, President, Glob. Health Living Found., to Anne
Gonzalez & Stephen A. Huffiman, Chair & Vice-Chair, Health & Aging Comm. (Apr. 19,
2016), https://www.50statenetwork.org/wp-content/uploads/2016/04/GHLF-OH-HB-505-
Comment-LetterSupport-4-19-16-locked.pdf.
110. Letters and Testimony, 50-ST. NETWORK, https://www.50statenetwork.org/letters-
and-testimony/ (last visited Apr. 9, 2017).
111. Rachelle Crow-Hercher, Patient Advocate, Glob. Health Living Found., Testimony
at Senate Health Policy Committee Consideration of HB-4812 (Feb. 16, 2016),
https://www.50statenetwork.org/wp-content/uploads/2016/02/GHLF-MI-Rachelle-HB4812-
Testimony-2-13-16.pdf.
112. Andrew Pollack, Makers ofHumira and Enbrel Using New Drug Patents to Delay
Generic Versions, N.Y. TiMEs (July 15, 2016),
https://www.nytimes.com/2016/07/16/business/makers-of-humira-and-enbrel-using-new-
drug-patents-to-delay-generic-versions.html.
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Takeda Pharmaceuticals." 3 The biologic Enbrel is an Amgen product, as is
Neupogen."' AbbVie makes Humira,"' and Janssen makes Remicade. 6
Each of these biologics is facing market competition from a biosimilar. In
addition, GHLF receives support from BIO, the international trade
association that has aggressively lobbied on behalf of its pharmaceutical
company members for state biosimilar legislation."' To the extent that
GHLF's lobbying efforts are aligned with those of its corporate sponsors, it
too may be taking advantage of the "patient-friendly" label to advance
legislation that is friendly to biologic manufacturers, but not necessarily
friendly to patients.
C. Physicians
Laws like those passed in Indiana and Louisiana do not necessarily help
patients."' If state laws make it harder to substitute interchangeable
biosimilars, there will be fewer substitutions, potentially forcing a patient to
stick with a more expensive biologic even if a safe and less expensive
biosimilar is available."' If laws require doctors to consent to substitution,
this requirement "may increase undue patient anxiety towards biosimilars
(and generics) and deter their use."1 20 If the FDA has determined that a
biosimilar is clinically indistinguishable from a biologic, why would doctors
support legislation that makes it more difficult for patients to obtain a
biosimilar?
Like pharmaceutical companies, doctors have good reason to stand behind
legislation that is labeled patient-friendly. In supporting such laws, the
physicians themselves give the appearance of supporting their patients'
interests and supporting such laws is good PR.
However, physicians may not be aware of their patients' interests. For
example, patients, but not physicians, will feel the economic consequences
of taking a more expensive biologic. A physician suffers no economic loss if
his or her patient must incur astronomical expenses related to medication.121
113. Our Partners, CREAKY JOINTS, https://creakyjoints.org/about-us/our-partners/ (last
visited Apr. 9, 2017).
114. Products, AMGEN, http://wwwext.amgen.com/products/ (last visited Apr. 9, 2017).
115. Products, ABBVIE, https://www.abbvie.com/our-science/products.html (last visited
Apr. 9, 2017).
116. Products, JANSSEN, http://wwwjanssen.com/products (last updated Apr. 3, 2017).
117. Id.
118. Kadin, supra note 47, at 420 (referencing Indiana law); H.B. No. 319, 41st Reg.
Sess. 391 (La. 2015), (referencing Louisiana law).
119. Kadin, supra note 47, at 421.
120. Id. at 425.
121. Aaron S. Kesselheim et al., The High Cost of Prescription Drugs in the United
States: Origins and Prospects for Reform, 316 JAMA 858, 861, 867 (2016) (explaining that
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In fact, because physicians often delegate medication authorization
paperwork to their nurses and other members of their office staff, they may
never learn what a biologic costs or how much a biosimilar can save their
patients. 2 2 Physicians may be too far removed from understanding the stakes
at issue in biosimilar legislation, rendering their testimony and support a poor
proxy for the patient voice.
IV. CONCLUSION
This essay challenges the assumption that state biosimilar legislation
advances patient interests by protecting patients' safety. Despite federal law
providing that a biologic prescribed by a physician may be substituted for an
interchangeable biosimilar without any additional communication or action,
numerous state laws have added communication requirements that make the
biologic to biosimilar exchange more difficult.1 23 Skeptical physicians and
patients may hesitate to accept a biosimilar in exchange for a biologic. As a
result, patients may have restricted access to less expensive forms of effective
medication.
Testimony on bills affecting biosimilars should exclude, or at least
deprioritize, testimony from companies with an economic stake in a
biosimilar bill's passage. Patients should be heard from first and patient
testimonials should outnumber industry testimonials. Doctors who wish to
support biosimilar legislation could be asked to show that their patients
support the doctors' legislative stance and that his or her patients will benefit
with respect to treatment options and cost if the legislation passes. The
assumption that doctors speak effectively for their patients must be
challenged.
Finally, though pharmacy organizations have opposed state legislation, in
general, and notification requirements, in particular, they have done so for
reasons unrelated to patient safety. Rather, the notification requirements have
been characterized as overly burdensome.124
State biosimilar legislation opponents need better advocates. If patient
advocacy groups' interests align with biological manufacturers who have a
financial interest in making it more difficult for biosimilars to enter a market,
then they cannot speak for patients who have different interests. What is
"physicians write prescriptions, pharmacists sell medications, and patients or their insurers
pay for them." Physicians often do not know the cost of the drugs they prescribe and are
unlikely to discuss the cost of the drug with the patient.).
122. The last time I discussed changing biologics with my rheumatologist, we settled on
Remicade. He never mentioned its cost, nor did he ask whether I had private insurance. He
never mentioned whether he was open to prescribing the Remicade biosimilar, which, by then,
was available in the U.S. See also Id. at 861.
123. Cauchi, supra note 68.
124. Virginia Bill First to Allow Biosimilar Substitution, supra note 104.
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needed is an army of informed patient advocates, armed with data about the
economic benefits of biosimilars and their scientifically-proven safety. Those
voices are missing.
I regret my decision to testify in support of Louisiana's biosimilar
legislation. I was lured by the siren song of patient safety concerns. I was
uninformed about what interchangeability meant for purposes of my own
medication. I now see what legislators saw: a sympathetic and articulate law
professor who suffered from a devastating disease and took the very
medication the biosimilar state laws implicated. I was a good choice for
purposes of lobbying in favor of notification requirements.
I hope that others read this article, state lawmakers and patients alike, and
look more closely at the laws that are being sold as friendly to patients like
myself The decision to support state biosimilar legislation must rest on much
more than a patient-friendly label and marketing campaign.
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